<DOC>
	<DOCNO>NCT00917813</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability 3 infusion KD-247 2 week HIV-1 seropositive individual ; determine pharmacokinetic parameter KD-247 administer ; assess effect KD-247 infusion plasma HIV-1 ribonucleic acid ( RNA ) load CD4+ T cell count .</brief_summary>
	<brief_title>A Study Anti-HIV Monoclonal Antibody KD-247</brief_title>
	<detailed_description>A minimum 6 active subject 3 placebo subject dose cohort complete 2 week infusion . A maximum 27 total subject dose KD-247 9 total receive placebo . Per cohort subject randomize active treatment receive iv infusion KD 247 2 hour dose visit . Subjects randomize placebo receive 2-hour iv infusion saline solution dose visit . Following first infusion KD-247 ( placebo ) subject study , 24-hour in-patient observation period next subject randomize within study . Dose escalation proceed safety data Day 18 subject lower-dose cohort review .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Have HIV1 infection confirm enzyme immunoassay ( EIA ) immunoblot . 2 . Are male female subject , age 1864 year . 3 . Demonstrate HIV1 RNA copy number 1000 100,000 copies/mL 2 measurement least 2 week apart . Measurements take screen and/or prior nonstudy related medical visit within 3 6 week Study Day 1 may consider . 4 . Have CD4+ T cell count &gt; 350 cells/mm3 2 measurement least 2 week apart . Measurements take screen one prior nonstudy medical visit within 3 6 week Study Day 1 may consider . 5 . Are treatment naïve antiretroviral drug least 8 week prior screen . 6 . By genotyping , sequence portion HIV envelope gene encode principal neutralize determinant consistent neutralization KD247 . 7 . Weigh 45120 kg . 8 . Have absolute neutrophil count &gt; 1000 cells/uL , hemoglobin ( Hgb ) &gt; 10 g/dL , platelet &gt; 100,000/uL . 9 . Have serum creatinine ≤1.5 mg/dL alanine transaminase ( ALT ) &lt; 2.5 time upper limit normal . 10 . Have 12lead electrocardiogram ( ECG ) without clinically significant abnormality opinion investigator . 11 . Female subject must : Women nonchildbearing potential , define either surgically sterile least 1year postmenopausal ( menstrual period least 2 year ) , Women childbearing potential use highly effective method contraception , Women childbearing potential negative serum beta human chorionic gonadotropin ( βHCG ) test result screen within 24 hour prior administration study drug . A negative urine pregnancy test within 24 hour prior administration study drug acceptable , serum pregnancy test result yet available . 12 . For heterosexual male subject , subject subject 's sexual partner must agree use acceptable method contraception entire study . Acceptable method include , limited , intrauterine device , diaphragm spermicide , condom , abstinence . Oral contraceptive alone acceptable method birth control . 13 . Be willing able provide write informed consent . 1 . Have history acquire immune deficiency syndrome ( AIDS ) define illness symptomatic HIV disease ( i.e. , Centers Disease Control [ CDC ] Class B C ) . 2 . Have receive monoclonal antibody therapy kind past . 3 . Received vaccination past 15 day prior study entry . 4 . Received antihistamine 6 week prior study entry . 5 . Received nonsteroidal antiinflammatory drug ( NSAIDs ) 56 day prior skin test . 6 . Any history anaphylaxis , asthma , hypersensitivity reaction vaccine drug infusion , angioedema , urticaria . 7 . Have treat follow within 3 month prior screen : interferon , cytokine , immunomodulators ; immunoglobulin therapy ; systemic corticosteroid ; cytotoxic drug ; ionize radiation . 8 . Have receive investigational agent within 60 day prior screen . 9 . Have condition , judgment investigator , may make subject 's participation study risky ; interfere collection interpretation PK data ; interfere ability subject adhere complete study . Such condition may include , limited , cardiovascular , respiratory , gastrointestinal/hepatic , neurologic , genitourinary disorder . 10 . Current alcohol drug use , judgment investigator , interfere subject 's ability comply protocol requirement . 11 . Have unexplained positive urine drug screen test illicit drug . 12 . Have confirm positive hepatitis B surface antigen ( HBsAg ) antibody hepatitis C virus ( HCV ) . 13 . Have use prescription within 14 day study initiation overthecounter ( OTC ) medication within 3 day study initiation , judgment investigator , would place individual risk interfere safety , tolerability , PK data . 14 . Have dosages/amounts drug change , schedule use new drug , judgment investigator , would place individual risk interfere safety , tolerability , PK data . 15 . Have recent history major surgery , internal organ biopsy , major trauma . 16 . Females pregnant breastfeeding , plan become pregnant study . 17 . Have mental condition render subject unable understand nature , scope , possible consequence study . 18 . Show positive reaction prick test KD247 , i.e. , ≥3 mm diameter great negative control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>KD-247</keyword>
	<keyword>treatment naive</keyword>
</DOC>